Cart
sales@molnova.com
Nexopamil
CAS No. 136033-49-3
Nexopamil( —— )
Catalog No. M34345 CAS No. 136033-49-3
Nexopamil (LU-49938) is a calcium channel antagonist and a 5-hydroxytryptamine 2A receptor antagonist.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 164 | In Stock |
|
| 10MG | 250 | In Stock |
|
| 25MG | 415 | In Stock |
|
| 50MG | 601 | In Stock |
|
| 100MG | 855 | In Stock |
|
| 200MG | 1163 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNexopamil
-
NoteResearch use only, not for human use.
-
Brief DescriptionNexopamil (LU-49938) is a calcium channel antagonist and a 5-hydroxytryptamine 2A receptor antagonist.
-
DescriptionNexopamil (LU-49938) is a calcium channel antagonist and a 5-hydroxytryptamine 2A receptor antagonist. Nexopamil inhibits 5-HT-induced contraction and proliferation of mesenchymal cells.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetCalcium Channel
-
RecptorCalcium Channel | 5-HT Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number136033-49-3
-
Formula Weight404.59
-
Molecular FormulaC24H40N2O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES[C@@](CCCN(CCCCCC)C)(C(C)C)(C#N)C1=CC(OC)=C(OC)C(OC)=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Stugeron
Cinnarizine is a drug derivative of piperazine, and characterized as an antihistamine and a calcium channel blocker.
-
Yangambin
Yangambin is a selective antagonist of the cardiovascular effects of platelet activating factor (PAF); it has hypotensive effect, which is probably due to a peripheral vasodilatation that involves, at least, the inhibition the Ca2+ influx through voltage-gated Ca2+ channels. Yangambin has central nervous system activity, it presents a depressant activity in the open field, forced swimming and pentobarbital sleeping time tests.
-
Mibefradil dihydroch...
Mibefradil dihydrochloride is an blocker of calcium channel with moderate selectivity for T-type Ca2+ channels (T-type and L-type currents with IC50s of 2.7 μM and 18.6 μM, respectively). Mibefradil dihydrochloride inhibits reversibly the T- and L-type currents with IC50 values of 2.7 and 18.6 μM, respectively.
